



Antibiotic Resistance and Therapy for *Helicobacter pylori* Infection

Guest Editors:

Prof. Dr. Stella I. Smith

Molecular Biology and
Biotechnology Department,
Yaba, Nigeria

Prof. Dr. Yoshio Yamaoka

Department of Environmental
and Preventive Medicine, Oita
University Faculty of Medicine,
Idaigaoka, Hasama-machi, Yufu,
Oita 879-5593, Japan

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editors

Potential topics for this Special Issue include but are not limited to:

- Alternative and complementary therapies for the treatment of *H. pylori* in the context of antibiotic resistance;
- New drug targets for *H. pylori* treatment in the post-antibiotic era;
- Molecular-based antibiotic susceptibility testing techniques for *H. pylori*;
- Mechanisms of *H. pylori* resistance: phenotypic/physiological changes in genomic mechanisms;
- Supplementation of *H. pylori* antibiotic therapy using probiotics;
- Clinical implication of drug resistance for *H. pylori* management.

The issue welcomes various types of submissions, such as original research papers, short communications, reviews, case reports, and perspectives.

Keywords:

- *H. pylori*
- antibiotic resistance
- alternative therapy
- drug targets
- probiotics





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)